Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Juan Pablo Sanchez-Luna,Pedro Martín,Antonio E Dager,Pablo D Charry,Javier R Beltrán,Ángel Sánchez-Recalde,Francesco Giannini,Antonio Gómez-Menchero,Manuel Pan,Alfonso Ielasi,Andrea Monastyrski,Marco Barbanti,Francisco Fernandez-Avilés,Marco Bruno Ancona,Abdurashid Mussayev,Juan Pablo De Brahi,Pablo Lamelas,Andrés Sánchez-Pérez,Melissa García Puerta,Miguel Ortiz,Jose Carlos Gonzalez-Gutiérrez,Giorgio Marengo,Javier Gómez,Esther Gonzalez-Bartol,Alexander Stepanenko,Itziar Gomez-Salvador,J Alberto San Román,Ignacio J Amat-Santos
DOI: https://doi.org/10.4244/EIJ-D-23-00344
2023-09-18
EuroIntervention
Abstract:Background: Transcatheter aortic valve replacement (TAVR) in non-calcified aortic regurgitation (NCAR) is an off-label procedure. The balloon-expandable Myval includes extra-large sizes (30.5 mm and 32 mm) of interest in this setting. Aims: We aimed to evaluate the safety and feasibility of Myval in NCAR. Methods: This was an international, multicentre, observational study that enrolled all consecutive patients with symptomatic severe NCAR undergoing TAVR with the Myval device. The images were centrally analysed. Results: A total of 113 patients were recruited, 64.6% were men, the mean age was 78.4±7.5 years, and the Society of Thoracic Surgeons score was 2.7±1.7%. Aortic root dilatation was present in 59.3% of patients, 7.1% were bicuspid, and the mean annular area was 638.6±106.0 mm2. The annular area was beyond the recommended range for extra-large sizes in 2.6% of cases, and additional volume was added in 92% (median 4 cc, up to 9 cc). The extra-large sizes were used in 95 patients (84.1%), and the mean oversizing was 17.9±11.0%. The technical success rate was 94.7%; the rate of residual ≥moderate aortic regurgitation was 8.9%, and the pacemaker rate was 22.2%. There were no cases of annular rupture, cardiac tamponade, or aortic dissection, but in 4 patients (3.5%) valve embolisation occurred (1 antegrade and 3 ventricular), all in cases with a tapered left ventricle outflow tract (p=0.007). Thirty-day and 1-year mortality were 5.3% and 9.7%, respectively. Technical success was associated with better survival (97.1% vs 72.7%; p=0.012), and valve embolisation was the main determinant of mortality (p=0.047). Conclusions: Myval is a feasible and safe option for selected non-operable patients with NCAR and demonstrated good midterm outcomes and lack of impact of oversizing on device durability.